MedTrace Logo

Treatment of Persistent Pulmonary Hypertension in Neonates With Nebulized Magnesium Sulfate

NCT06603766 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-02-05

Study results available
· View outcomes & findings →

Summary

we conducted this study to compare between effect of nebulized and intravenous magnesium sulfate (MgSO₄) for better treatment of persistent pulmonary hypertension of neonates with less side effects.

Conditions

  • Magnesium Sulfate - PPHN

Interventions

DRUG

IV Magnesium Sulfate

MgSO₄'s mechanism in PPHN includes activating cellular processes, modulating membrane excitability, and acting as a physiological calcium antagonist. It exerts sedative, muscle relaxant, and bronchodilatory properties, while concurrently inducing a state of alkalosis.

DRUG

Inhalational magnesium sulfate

It gives us the same mechanism of action as IV MgSO4 with less side effects.

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Osama Z. El Feky, Professor · Pediatrics Department, Faculty of Medicine, Benha University, Benha, Egypt.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Hour
Max Age
3 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2023-09-28
Completion
2023-09-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06603766 on ClinicalTrials.gov